ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04234568 (A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
purposeThe next generation of theranostics studies is looking at novel combinations with radiation sensitizers to enhance peptide receptor radionuclide therapy's efficacy. In this study, we present safety and efficacy data from a multicenter phase I study of a [177Lu]lutetium-dotatate-triapine combination in patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET). PATIENTS AND
methodsThe study consisted of 2 phases (part A: dose escalation; part B: dose expansion) administering the recommended phase II doses (RP2D) for the 2 agents. All patients received 200 mCi of [177Lu]lutetium-dotatate on day 1 of four 8-week cycles, in combination with oral triapine administered at assigned dose levels (100, 150, or 200 mg) from day 1 to day 14 of each cycle.
resultsA total of 31 (A: 15; B: 16) patients received treatment. Across the study, 9 patients experienced dose-limiting toxicities: grade 3 anemia (n = 1), grade 5 cardiac arrest (unrelated to investigational product; n = 1), and grade 4 neutropenia (n = 7). Based on the overall safety and pharmacokinetics data, a [177Lu]lutetium-dotatate (200 mCi) plus triapine (150 mg) dose was selected as the RP2D for the expansion phase. Grade ≥3 treatment-related adverse events were observed in 77% of patients: anemia (23%), nausea and vomiting (3%), lymphopenia (58%), neutropenia (35%), and decreased white blood cell count (39%). The majority of cytopenias were transient and resolved within 2 weeks. Among the 28 evaluable patients, the objective response rate was 21.4%, and the median progression-free survival has not been reached (median follow-up period, 23.7 months).
conclusionsThe combination of [177Lu]lutetium-dotatate (200 mCi) and oral triapine (150 mg D1-14) was well tolerated and demonstrated preliminary activity in patients with well-differentiated GEP-NET (NCT04234568).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.